Table 1.
Baseline characteristics according to diagnosis
| Preclinical AD (n = 438) |
Prodromal AD (n = 729) |
Mild AD dementia (n = 1867) |
Moderate to severe AD dementia (n = 234) |
p-value overall group difference |
|
|---|---|---|---|---|---|
| Age (years) | 73 (7) | 72 (7) | 73 (9) | 75 (10) | <0.01a |
| Male (n) | 204 (47%) | 417 (57%) | 781 (42%) | 74 (33%) | <0.01 |
| MMSE (0-30, median (IQR)) (n=3252) | 29 (28-30) | 27 (26-29) | 22 (19-24) | 16 (13,19) | <0.01b |
| APOE ε4 genotype* (n) (n=1984) | 210 (49%) | 466 (66%) | 554 (71%) | 35 (51%) | <0.01 |
| Abnormal CSF total tau* (n) (n=1563) | 87 (38%) | 346 (57%) | 535 (80%) | 47 (82%) | <0.01 |
| Follow-up years (median (IQR)) | 3.8 (2-4.5) | 3.9 (2.5-4.8) | 2.0 (1.5-2.5) | 2.0 (1.2-2.3) | <0.01c |
| Progression to next clinical disease stage (n) | 87 (20%) | 325 (45%) | 569 (30%) | NA | NA |
| Death at follow-up (n) | 12 (3%) | 76 (10%) | 215 (12%) | 54 (23%) | NA |
| Participants by cohort (n ADC /ADNI /AIBL /DESCRIPA /Gothenburg /ICTUS) | 40/180/191 /23 /4 /0 | 140 /449 /73 /49/18 / 0 | 507 /224 /69 /0/1 / 1066 | 64 /1/3 /0/0 / 166 | NA |
Mean (SD), unless otherwise specified. In Tukey posthoc:
a
Moderate to severe AD dementia older than the MCI and Mild AD dementia group;
b
All groups significantly different from each other;
c
Normal cognition and MCI longer follow-up than dementia groups
*
Available in subset of cohorts, APOE not for ICTUS